News

August 12, 2019August 12, 2019

IBD Patients at Higher Risk of Developing Type 2 Diabetes, Study in Denmark Suggests

News

Patients with inflammatory bowel disease (IBD) are at higher risk of developing type 2 diabetes, compared with the general population, according to a study conducted in Denmark. The study, “Inflammatory ... Read more

August 9, 2019August 9, 2019

NP-178 Becomes Algernon’s Lead Candidate for Treating IBD

News

NP-178 (emoxypine), an oral small molecule being repurposed by Algernon Pharmaceuticals, has become the company’s lead candidate to treat inflammatory bowel disease (IBD). Emoxypine is one of the most commercialized generic ... Read more

August 7, 2019August 7, 2019

Edinburgh has One of the Highest Rates of IBD in the World, Study Reports

News

Edinburgh, in Scotland, has one of the highest recorded rates of inflammatory bowel disease (IBD) in the world, higher than what is currently recognized, a study has found. The study, ... Read more

August 5, 2019August 5, 2019

Camligo Trial Yields Mixed Results in Patients with Pouchitis

News

Atlantic Healthcare’s Camligo (alicaforsen enema) did not meet the primary endpoints of the Phase 3 clinical trial that aimed to evaluate the efficacy of the drug in patients with pouchitis. ... Read more

August 2, 2019August 2, 2019

Editing Gut Bacteria Reduces Colorectal Cancer in Mice with Colitis

News

Tweaking the types of bacteria living in the gut, or gut microbiota, can prevent bowel cancer in mice with inflammatory bowel disease (IBD), a new study has found. By restricting ... Read more

July 30, 2019July 30, 2019

Clinical Trial in Israel Will Evaluate Cannabidiol-based Product for Crohn’s Disease

News

The Israel-based company Stero Biotechs announced it soon will conduct a study to test a cannabidiol (CBD)-based solution as a potential treatment for steroid-dependent Crohn’s disease (SDCD). SDCD is a ... Read more

July 29, 2019July 29, 2019

CHMP Favors Approving Stelara to Treat Moderate to Severe Ulcerative Colitis in EU

News

The Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has recommended that Stelara (ustekinumab) be approved in Europe to treat moderately to severely active ... Read more

July 26, 2019July 26, 2019

Hadlima, Biosimilar to Humira, Receives FDA Approval to Treat Autoimmune Diseases

News

Hadlima (adalimumab-bwwd) — an antibody biosimilar to AbbVie‘s Humira (adalimumab) — has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of a number of autoimmune ... Read more

July 24, 2019July 24, 2019

Innovation and Alfasigma Ink Pact to Develop and Commercialize Brilacidin for Types of IBD

News

Innovation Pharmaceuticals now has a global licensing agreement with Alfasigma for the development and commercialization of the therapy Brilacidin for treating ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS), types of inflammatory bowel disease (IBD). ... Read more

July 22, 2019July 22, 2019

Remicade Biosimilar CT-P13 Found Safe, Effective for IBD Treatment in Italian Study

News

CT-P13, a biosimilar of Remicade (infliximab), is safe and effective for the treatment of inflammatory bowel disease (IBD), a study suggests. The study, “Infliximab biosimilar CT-P13 is effective and safe ... Read more